Who owns BRIDGEBIO PHARMA INC?
- CUSIP Number: 10806xad4
Tip: Access positions for across all investors
Analyze quarterly positions in Bridgebio Pharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Bridgebio Pharma stock
Who bought or sold BRIDGEBIO PHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Linden Advisors | 239M | $269M | 12% | Mar 2026 |
|
| Ing Investment Management | 167M | $187M | 456% | Mar 2026 |
|
| Context Capital Management | 57M | $63M | -20% | Jun 2026 |
|
| MacKay Shields | 33M | $37M | 0% | Jun 2026 |
|
| Lord, Abbett & Co | 29M | $33M | 100% | Mar 2026 |
|
| Wolverine Asset Management | 28M | $31M | -68% | Mar 2026 |
|
| Silverback Asset Management | 22M | $25M | -18% | Mar 2026 |
|
| Laurion Capital Management | 19M | $22M | 0% | Mar 2026 |
|
| Advent Capital Management | 19M | $21M | -8% | Mar 2026 |
|
| State Street Corporation | 15M | $17M | -4% | Mar 2026 |
|
| BlackRock | 12M | $13M | 25% | Mar 2026 |
|
| Wells Fargo & Company | 8.9M | $10M | -41% | Mar 2026 |
|
| FMR | 8.7M | $9.7M | 0% | Mar 2026 |
|
| OZ Management | 7.0M | $7.9M | 100% | Mar 2026 |
|
| Lazard Asset Management | 6.4M | $71k | 15% | Mar 2026 |
|
| SSI Investment Management | 6.1M | $6.8M | 11% | Mar 2026 |
|
| Calamos Advisors | 5.0M | $5.6M | 0% | Mar 2026 |
|
| Goldman Sachs Group | 4.5M | $5.0M | 369% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 3.7M | $4.1M | 100% | Mar 2026 |
|
| Toronto-Dominion Bank | 3.6M | $4.1M | 100% | Mar 2026 |
|
| RWC Asset Management | 3.1M | $3.5M | -5% | Jun 2026 |
|
| Jane Street | 2.8M | $3.1M | 100% | Mar 2026 |
|
| Bnp Paribas Investment Partners | 2.5M | $2.8M | 0% | Mar 2026 |
|
| Agf Management | 2.5M | $2.8M | -64% | Mar 2026 |
|
| Citigroup | 2.1M | $2.4M | 100% | Mar 2026 |
|
| Leucadia National Corporation | 1.5M | $1.7M | 100% | Mar 2026 |
|
| Bank of New York Mellon | 1.0M | $1.1M | 400% | Mar 2026 |
|
| Universal- Beteiligungs- und Servicegesellschaft mbH | 600k | $677k | 0% | Mar 2026 |
|
| Royal Bank of Canada | 450k | $507k | 100% | Mar 2026 |
|
| Sei Investments | 377k | $422k | 4% | Mar 2026 |
|
| Shenkman Capital Management | 376k | $423M | -96% | Mar 2026 |
|
| UBS Group | 327k | $366k | 100% | Mar 2026 |
|
| Deutsche Bank Aktiengesellschaft | 300k | $335k | 100% | Mar 2026 |
|
| Wellesley Investment Advisors | 210k | $237M | 100% | Mar 2026 |
|
| Oppenheimer Asset Management | 105k | $117k | 100% | Mar 2026 |
|
| ADAR1 Capital Management | 45k | $4.9M | 100% | Mar 2026 |
|
| Virtus ETF Advisers | 38k | $43k | 100% | Mar 2026 |
|
| Stephens | 32k | $35k | -3% | Jun 2026 |
|
| Balboa Wealth Partners | 15k | $17k | 100% | Mar 2026 |
|
| Wiley Bros.-aintree Capital | 15k | $17k | 100% | Mar 2026 |
|
| Insigneo Advisory Services | 13k | $15k | -19% | Mar 2026 |
|
| SG Americas Securities | 6.1k | $680k | -40% | Mar 2026 |
|
Who sold out of Bridgebio Pharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| CSS | Dec 2025 | 27M | $30M |
| Polar Capital Holdings | Dec 2025 | 24M | $27M |
| Sona Asset Management | Dec 2025 | 22M | $25M |
| Nuveen | Dec 2025 | 20M | $23M |
| Davidson Kempner Capital Management | Dec 2025 | 10M | $11M |
| Readystate Asset Management | Dec 2025 | 7.0M | $7.9M |
| Ameriprise Financial | Dec 2025 | 7.0M | $7.9M |
| Citadel Advisors | Dec 2025 | 5.0M | $5.6M |
| Oaktree Capital Management | Dec 2025 | 2.6M | $2.9M |
| Ares Systematic Credit | Dec 2025 | 2.1M | $2.4M |
| Morgan Stanley | Dec 2025 | 1.5M | $1.7M |
| Barclays | Dec 2025 | 1.0M | $1.1M |
| Wealth Enhancement Advisory Services | Dec 2025 | 12k | $13k |